Tundra Space

Tundra Space

Book DemoDirectoryLog InSign Up

Clinical Research Directory

Browse clinical research sites, groups, and studies.

SitesGroupsStudies
Back to Studies
RECRUITING
NCT06488105
PHASE2

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial

Sponsor: Wake Forest University Health Sciences

View on ClinicalTrials.gov

Summary

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being evaluated for acute coronary syndrome. The overarching goals of this proposal are to (1) determine the efficacy of EMERALD at lowering low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein cholesterol (non-HDL-C) among at-risk Emergency Department (ED) patients who are not already receiving guideline-directed outpatient preventive care and (2) inform our understanding of patient adherence and determinants of implementation for ED-based cardiovascular disease prevention strategies.

Official title: Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) Trial

Key Details

Gender

All

Age Range

40 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

130

Start Date

2024-08-05

Completion Date

2029-03-31

Last Updated

2026-02-27

Healthy Volunteers

No

Conditions

Lipid DisorderHypercholesterolemiaCardiovascular DiseasesAtherosclerosis

Interventions

DRUG

Statin (rosuvastatin 10 or 40 mg daily, depending on risk)

moderate- or high-intensity statin (either rosuvastatin 10 mg daily or rosuvastatin 40 mg daily)

BEHAVIORAL

Healthy Lifestyle Counseling

Healthy lifestyle counseling based off the American Heart Association's Life Essential 8 framework

OTHER

Outpatient Followup

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) intervention patients will receive either cardiology or primary care referral (depending on risk level) and usual care patients will receive a primary care referral

Locations (1)

Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States